



Enanta Pharmaceuticals to Present at the Credit Suisse 25th Annual Healthcare Conference

October 26, 2016

Presentation to be Webcast on November 7, 2016 at 1:30 P.M. MT

WATERTOWN, Mass.--(BUSINESS WIRE)--Oct. 26, 2016-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a presentation followed by a question and answer session with investors at the Credit Suisse 25th Annual Healthcare Conference on Monday, November 7 at 1:30 p.m. MT.

A live webcast and replay of the presentation will be accessible by visiting the "Calendar of Events" section on the "Investors" page of Enanta's website at www.enanta.com. The webcast replay will be available following the conference and will be archived for approximately 30 days.

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta's research and development efforts are currently focused on four disease targets: Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH) and Respiratory Syncytial Virus (RSV).

Enanta has discovered novel protease inhibitors and NS5A inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). Enanta's protease inhibitors, developed through its collaboration with AbbVie, include paritaprevir, which is contained in AbbVie's marketed DAA regimens for HCV, and glecaprevir (ABT-493), Enanta's second protease inhibitor, which AbbVie is developing in Phase 3 studies in combination with pibrentasvir (ABT-530), AbbVie's NS5A inhibitor. Enanta has also discovered a cyclophilin inhibitor, EDP-494, a novel host-targeting mechanism for HCV, which is now in a clinical proof-of-concept study in HCV patients, and EDP-305, an FXR agonist product candidate for NASH, currently in Phase 1 clinical development. Please visit www.enanta.com for more information on our programs and pipeline.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20161026005092/en/>

Source: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com